Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
1.380
-0.030 (-2.13%)
At close: Oct 31, 2024, 4:00 PM
1.390
+0.010 (0.72%)
After-hours: Oct 31, 2024, 6:39 PM EDT
Atossa Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Atossa Therapeutics stock have an average target of 6.25, with a low estimate of 6.00 and a high estimate of 6.50. The average target predicts an increase of 352.90% from the current stock price of 1.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ATOS stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +334.78% | Oct 31, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.25 → $6.5 | Strong Buy | Maintains | $6.25 → $6.5 | +371.01% | Sep 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +334.78% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +334.78% | Jun 28, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.22
from -0.24
EPS Next Year
-0.28
from -0.22
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 171.6M | ||
| Avg | n/a | n/a | 55.6M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.22 | -0.27 | -0.22 | ||
| Avg | -0.22 | -0.28 | -0.24 | ||
| Low | -0.22 | -0.28 | -0.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.